Abstract
Zuranolone, at a dose of 50 mg/day, led to significant improvement in depressive symptoms relative to placebo at two weeks in women with postpartum depression, a Phase 3 trial has found. Study results were published online July 26, 2023, in the American Journal of Psychiatry. In early August, the Food and Drug Administration (FDA) approved zuranolone for the treatment of postpartum depression.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
